Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia

Connor Walsh; Anthony Hunter; Terra Lasho; Christy Finke; Rhett Ketterling; Rami Komrokji; Ayalew Tefferi; Abhishek Mangaonkar; Matthew Howard; Naseema Gangat; Aref Al-Kali; Najla Al Ali; Eric Padron; Mrinal M. Patnaik

doi:10.1038/s41375-022-01551-y

Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia

Connor Walsh, Anthony Hunter, Terra Lasho, Christy Finke, Rhett Ketterling, Rami Komrokji, Ayalew Tefferi, Abhishek Mangaonkar, Matthew Howard, Naseema Gangat, Aref Al-Kali, Najla Al Ali, Eric Padron, Mrinal M. Patnaik

Hematology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	1693-1696
Number of pages	4
Journal	Leukemia
Volume	36
Issue number	6
DOIs	https://doi.org/10.1038/s41375-022-01551-y
State	Published - Jun 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-022-01551-y

Cite this

@article{f384b34dd1a54ec2af3fa6f1ab5e66e1,

title = "Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia",

author = "Connor Walsh and Anthony Hunter and Terra Lasho and Christy Finke and Rhett Ketterling and Rami Komrokji and Ayalew Tefferi and Abhishek Mangaonkar and Matthew Howard and Naseema Gangat and Aref Al-Kali and Ali, {Najla Al} and Eric Padron and Patnaik, {Mrinal M.}",

note = "Funding Information: We would like to acknowledge the “Henry J. Predolin Leukemia Foundation” at Mayo Clinic for supporting the CMML biobank and all the patients at both institutions for participating in research studies. Funding Information: MP has received research funding from Kura Oncology and Stem Line Pharmaceuticals. The remaining authors declare no competing interests. ",

year = "2022",

month = jun,

doi = "10.1038/s41375-022-01551-y",

language = "English (US)",

volume = "36",

pages = "1693--1696",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia

AU - Walsh, Connor

AU - Hunter, Anthony

AU - Lasho, Terra

AU - Finke, Christy

AU - Ketterling, Rhett

AU - Komrokji, Rami

AU - Tefferi, Ayalew

AU - Mangaonkar, Abhishek

AU - Howard, Matthew

AU - Gangat, Naseema

AU - Al-Kali, Aref

AU - Ali, Najla Al

AU - Padron, Eric

AU - Patnaik, Mrinal M.

N1 - Funding Information: We would like to acknowledge the “Henry J. Predolin Leukemia Foundation” at Mayo Clinic for supporting the CMML biobank and all the patients at both institutions for participating in research studies. Funding Information: MP has received research funding from Kura Oncology and Stem Line Pharmaceuticals. The remaining authors declare no competing interests.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85127315832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127315832&partnerID=8YFLogxK

U2 - 10.1038/s41375-022-01551-y

DO - 10.1038/s41375-022-01551-y

M3 - Article

C2 - 35351982

AN - SCOPUS:85127315832

SN - 0887-6924

VL - 36

SP - 1693

EP - 1696

JO - Leukemia

JF - Leukemia

IS - 6

ER -

Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this